peoplePerson
Shaomeng Wang
Shaomeng Wang is the medicinal chemist behind some of the first clinical MDM2 inhibitors and PROTAC degraders.
Designed MDM2 inhibitors, BET and AR degraders, and the first STAT3 degrader to enter clinical trials; founder of several oncology biotechs.
Role
Warner-Lambert/Parke-Davis Professor in Medicine; Director, Rogel Cancer Center Drug Discovery
Institution
Specialisms
Medicinal chemistryProtein degradersMDM2 and BET inhibitors
| Title | Journal | Year |
|---|---|---|
| A selective small-molecule STAT3 degrader achieves complete tumor regression in vivo | Cancer Cell | 2019 |